Concourse Financial Group Securities, Inc. Cardiol Therapeutics Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.67 Billion
Q4 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q4 2024 Feb 13, 2025	BUY	$1.25 - $2.07 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$1.83 - $2.48 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$1.67 - $2.97 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.88 - $2.06 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.67 - $1.0 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.76 - $1.19 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.76 - $1.19 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.45 - $0.97 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.47 - $0.81 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.48 - $1.0 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.02 - $1.41 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.03 - $2.05 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.25 - $2.31 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$1.83 - $4.86 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$2.03 - $4.8 $0 - $0

Others Institutions Holding CRDL

# of Institutions

Shares Held

7.58M

Call Options Held

4.9K

Put Options Held

3.8K

Tejara Capital LTD London, X0

3.12M
Shares

$3.58 Million
2.61% of portfolio
Advisor Shares Investments LLC Bethesda, MD

882K
Shares

$1.01 Million
0.23% of portfolio
Mmcap International Inc. Spc Grand Cayman, E9

796K
Shares

$914,968
0.31% of portfolio
Pvg Asset Management Corp Golden, CO

487K
Shares

$560,389
3.54% of portfolio
Cambridge Investment Research Advisors, Inc.

331K
Shares

$380,080
0.0% of portfolio

View Full List

About Cardiol Therapeutics Inc.

Ticker CRDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 61,942,500
Market Cap $71.2M
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...

More about CRDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account